Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
This article compares yields from SP 500 funds and multi-asset retirement portfolios, detailing factors that influence income streams.
25,151 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
A biotech stock that sprinted 685% in months drew a sizeable institutional bet as it pressed ahead with two FDA filin...
Cyber threats keep evolving, and investors are eyeing cybersecurity leaders. This guide breaks down whether palo alto...
A sharp one-week move in a space stock can redefine risk and opportunity. This guide explains why rocket stock skyroc...
As electricity demand climbs, NuScale Power presents a rare risk reward. This piece lays out one compelling buy reaso...
Cameco stock sliding below $120 has investors weighing risk and opportunity. This guide breaks down the uranium outlo...
Two AI-focused names have pulled back recently, but their paths diverge. This guide breaks down why palantir sandisk ...
The AI era has reshaped Palantir's role in enterprise data. This guide weighs the buy, sell, hold case for 2026 with ...
SpaceX stocks have traded below their IPO price, stirring questions about value and risk. This guide delivers a pract...
Stratasys has long been a trailblazer in 3D printing, but the road ahead is proving tougher amid competition and cost...
A leading AI company hints at a monumental goal: $9 trillion in market value. We explore what that could mean for inv...
Curious about a nuclear-tech stock with big growth potential? This guide breaks down the case for buying oklo stock t...